Powered by Lexis+®
Jurisdiction(s):
United Kingdom
Related Content
CASE STUDY

“It really is saving us a huge number of hours over the days, weeks and months. Having more relevant support at hand, not having to draft or review documents them from scratch - it all adds up.”

Southampton FC

Access all documents on Peer group analysis

Peer group analysis meaning

What does Peer group analysis mean?
Peer group analysis describes the comparison and ranking of an investment manager or fund against a defined universe of broadly similar strategies, typically presented as percentile or quartile tables. In legal practice it is used by pension scheme trustees, charity trustees, insurers and other asset owners to evidence investment due diligence, performance monitoring and fiduciary oversight, and is often referenced in investment management agreements (IMAs), prospectuses and reporting policies. It is not defined in legislation or case law; it is a descriptive industry term used across investment and pensions contexts. Data are drawn from third‑party surveys and databases (historically CAPS and WM; now commonly CAMRADATA, eVestment, Morningstar/Lipper and consultant universes). Key legal points include: describing the chosen peer universe and methodology; stating whether results are gross or net of fees; identifying time periods and risk measures; and recognising limitations (for example survivorship, style and size biases). It should not be treated as a regulatory “benchmark” unless expressly designated as such. Peer group outcomes may inform fee negotiations, performance‑related fee adjustments, and manager review or termination triggers, and may appear as expert evidence in performance‑related disputes. Usage and meaning are broadly consistent across England & Wales, Scotland, Northern Ireland and Ireland.
Speed up all aspects of your legal work with tools that help you to work faster and smarter. Win cases, close deals and grow your business–all whilst saving time and reducing risk.

View the related News about Peer group analysis

NEWS
UK and EU life sciences briefing: AI research guidance, UK clinical trials reforms, PFAS impact on medicines, Pharmacopoeia/ATMP updates, device standards, advertising rulings, AstraZeneca v Glenmark SPC injunction

In this issue: Research and development Pharmaceuticals—regulatory framework Advanced therapeutics Commercialisation Medical devices Advertising of medicines Intellectual property Daily and weekly news alerts New and updated content Trackers Useful information There will be no Weekly Highlights on 24 April 2025 Research and development Commission updates guidelines on responsible use of generative AI in research On 10 April 2025, the European Commission’s Directorate‑General for Research and Innovation released the second edition of its guidance on the responsible use of generative artificial intelligence (AI) in research. Targeted at researchers, research organisations and funders, the update complements the EU Artificial Intelligence Act (EU AI act). It details core principles—reliability, truthfulness, respect and accountability—for AI use. The guidance also calls for transparency about the AI tools employed, safeguards for sensitive data and intellectual property rights, and bans heavy reliance on AI in peer review. See: LNB News 10/04/2025 30...

Read More Right Arrow